Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.

Jun 19, 2018The Journal of family practice

Safety of Once-Weekly Glucagon-like Peptide-1 Treatments in People with Type 2 Diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗

Abstract

Four once-weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved for treating type 2 diabetes.

GLP-1 RAs can lower HbA1c levels and may induce weight loss in patients with type 2 diabetes.
These medications are associated with a reduced risk of hypoglycemia compared to other antihyperglycemic agents.
Safety profiles of once-weekly GLP-1 RAs vary, showing differences in adverse events related to macrovascular, microvascular, gastrointestinal, and injection-site reactions.
Healthcare providers should consider these safety differences when prescribing GLP-1 RAs for diabetes management.

AI simplified

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been found efficacious in the treatment of type 2 diabetes (T2D), demonstrating the ability to lower HbA1c, and having the potential for inducing weight loss and reducing the risk of hypoglycemia, compared with other antihyperglycemic agents. Currently, 4 once-weekly (OW) GLP-1 RAs are approved: albiglutide, dulaglutide, exenatide ER, and recently, semaglutide. This review compares the relative safety of OW GLP-1 RAs, as well as their safety in comparison to other antihyperglycemic agents, using safety data reported in key sponsor-led phase 3 studies of the 4 OW GLP-1 RAs. The favorable safety profiles of OW GLP-1 RAs, added to their efficacy and the favorable weekly dosing regimen, make these agents appropriate options for patients with T2D. However, there are key differences within this class of drugs in macrovascular, microvascular, gastrointestinal and injection-site reaction adverse events, and these should be considered when healthcare providers are prescribing therapy.

Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.

Abstract

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief